TuHURA Biosciences raises $15.6 million in equity financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/3/2026
- Wall St climbs after Fed's Waller says he could support rate hold
- Fed’s Waller open to September rate hold - if disinflation holds up
- Broadcom raises AI chip forecast as Big Tech keeps writing bigger checks
- Nvidia to acquire AI platform Hugging Face in landmark $12.9B deal
- Tesla to unveil Cybercab Texas today, details are few
TuHURA Biosciences Provides Corporate Update Following Recent Financing
December 11, 2025 7:30 AM ESTCompany's lead Phase 3 program of IFx-2.0 as adjunctive therapy with Keytruda® (pembrolizumab) as a first-line therapy for advanced and metastatic Merkel cell carcinoma (MCC), conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA) targeting completion of enrollment Q4-2026
A mini KOL symposium held on December 5, 2025, provided the scientific rational for targeting VISTA in AML and the clinical applications in combination with a menin inhibitor in NPM1... More
